Ganetespib: Additional Phase II data

Additional data from an open-label, U.S. Phase II trial in 76 evaluable patients showed that ganetespib produced an overall response rate (ORR) of 5.3% and a disease control rate (DCR) of 54% at week 8. In 8 evaluable anaplastic lymphoma kinase (ALK)-positive patients, ganetespib led to an ORR and DCR of 50% and 88%, respectively, with 6 patients experiencing tumor shrinkage in their target lesions. In 48 evaluable patients in the epidermal growth factor receptor (EGFR) and K-Ras wild-type cohorts, ganetespib led to an ORR and DCR of 8% and 58%, respectively, with 15 patients experiencing tumor shrinkage in their target lesions. In 13 evaluable patients in the K-Ras mutation cohort, ganetespib led to an ORR of 38%, with 8 patients experiencing tumor shrinkage in their target lesions. In 14 evaluable patients in the EGFR mutation cohort, ganetespib led to an ORR of 50%, with 5 patients experiencing tumor shrinkage in their target lesions. Patients received once-weekly 200 mg/m 2 ganetespib as a 1-hour infusion for 3 weeks of a 4-week cycle. Data were presented at the American Society of Clinical Oncology meeting in Chicago in June. ...